112 related articles for article (PubMed ID: 32918090)
21. [Biological drugs in inflammatory bowel disease: Management and care].
Guerra I; Bermejo F
Rev Esp Enferm Dig; 2015 Jul; 107(7):454. PubMed ID: 26140643
[No Abstract] [Full Text] [Related]
22. Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome.
Spagnuolo R; Cosco C; Mancina RM; Ruggiero G; Garieri P; Cosco V; Doldo P
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(2 Suppl):102-107. PubMed ID: 28724171
[TBL] [Abstract][Full Text] [Related]
23. Editorial: Gastrointestinal 2020: Novel inflammatory bowel disease treatments and therapeutic drug monitoring.
Torres J; Declerck P
Curr Opin Pharmacol; 2020 Dec; 55():iii-vi. PubMed ID: 33357460
[No Abstract] [Full Text] [Related]
24. Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease.
Atreya R; Neurath MF
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):790-802. PubMed ID: 30353856
[TBL] [Abstract][Full Text] [Related]
25. Adherence to a predefined vaccination program in patients with inflammatory bowel disease.
Ruiz-Cuesta P; González-Alayón C; Jurado-García J; Iglesias-Flores EM; Barranco-Quintana JL; García-García L; Salgueiro-Rodríguez IM; Benitez-Cantero JM; García-Sánchez V
Gastroenterol Hepatol; 2016; 39(6):385-92. PubMed ID: 26601992
[TBL] [Abstract][Full Text] [Related]
26. Biological Therapy for Inflammatory Bowel Disease During the COVID-19 Pandemic: Experiences From a Tertiary IBD Service.
Markovic S; Ivanovski TK; Zogovic B; Cvetkovic M; Svorcan P
Inflamm Bowel Dis; 2020 Nov; 26(12):e152. PubMed ID: 33043961
[No Abstract] [Full Text] [Related]
27. [SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID].
Lee YJ; Kim SE; Park YE; Chang JY; Song HJ; Kim DH; Yang YJ; Kim BC; Lee JG; Yang HC; Choi M; Myung SJ;
Korean J Gastroenterol; 2021 Aug; 78(2):117-128. PubMed ID: 34446634
[TBL] [Abstract][Full Text] [Related]
28. Beyond tumor necrosis factor: next-generation biologic therapy for inflammatory bowel disease.
Podolsky DK
Dig Dis; 2009; 27(3):366-9. PubMed ID: 19786766
[TBL] [Abstract][Full Text] [Related]
29. Safety of Drugs During Previous and Current Coronavirus Pandemics: Lessons for Inflammatory Bowel Disease.
Sebastian S; Gonzalez HA; Peyrin-Biroulet L
J Crohns Colitis; 2020 Nov; 14(11):1632-1643. PubMed ID: 32520312
[TBL] [Abstract][Full Text] [Related]
30. Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance and Healthcare Utilization in Patients with Inflammatory Bowel Disease.
Chablani SV; Ramos-Rivers C; Binion DG; Szigethy E
Dig Dis Sci; 2018 Sep; 63(9):2482-2484. PubMed ID: 30022454
[No Abstract] [Full Text] [Related]
31. Therapeutic Drug Monitoring in IBD: Prospective Promise Unfulfilled.
Govani SM; Waljee AK
Am J Gastroenterol; 2017 May; 112(5):670-672. PubMed ID: 28323274
[No Abstract] [Full Text] [Related]
32. Therapeutic immunoglobulin A antibody for dysbiosis-related diseases.
Shinkura R
Int Immunol; 2021 Nov; 33(12):787-790. PubMed ID: 34492105
[TBL] [Abstract][Full Text] [Related]
33. How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.
Sarzi-Puttini P; Marotto D; Antivalle M; Salaffi F; Atzeni F; Maconi G; Monteleone G; Rizzardini G; Antinori S; Galli M; Ardizzone S
Autoimmun Rev; 2020 Jul; 19(7):102574. PubMed ID: 32376399
[TBL] [Abstract][Full Text] [Related]
34. [Biological agents and small molecules in the treatment of inflammatory bowel disease].
Cheng XY; Li JN
Zhonghua Nei Ke Za Zhi; 2021 Apr; 60(4):376-379. PubMed ID: 33765710
[TBL] [Abstract][Full Text] [Related]
35. Safety of biologics in inflammatory bowel disease patients with COVID-19.
Weissman S; Aziz M; Smith WL; Elias S; Swaminath A; Feuerstein JD
Int J Colorectal Dis; 2021 Sep; 36(9):2051-2055. PubMed ID: 34131784
[TBL] [Abstract][Full Text] [Related]
36. Severe COVID-19 in inflammatory bowel disease patients in a population-based setting.
Creemers RH; Rezazadeh Ardabili A; Jonkers DM; Leers MPG; Romberg-Camps MJ; Pierik MJ; van Bodegraven AA
PLoS One; 2021; 16(10):e0258271. PubMed ID: 34610041
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California.
Gubatan J; Levitte S; Balabanis T; Patel A; Sharma A; Habtezion A
Gastroenterology; 2020 Sep; 159(3):1141-1144.e2. PubMed ID: 32387541
[No Abstract] [Full Text] [Related]
38. How to manage the logistics of biological therapy.
Headon B
J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():42. PubMed ID: 26990005
[No Abstract] [Full Text] [Related]
39. Inflammatory Bowel Disease Management in a Romanian Tertiary Gastroenterology Center: Challenges of the COVID-19 Pandemic.
Vadan R; Iacob R; Costache R; Stroie T; Saizu IA; Iacob S; Gheorghe L; Diculescu M; Gheorghe C
J Gastrointestin Liver Dis; 2020 Dec; 29(4):549-553. PubMed ID: 33331349
[TBL] [Abstract][Full Text] [Related]
40. Characteristics and Prognosis of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic in the Basque Country (Spain).
Rodríguez-Lago I; Ramírez de la Piscina P; Elorza A; Merino O; Ortiz de Zárate J; Cabriada JL
Gastroenterology; 2020 Aug; 159(2):781-783. PubMed ID: 32330477
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
